{"id":"NCT03363841","sponsor":"Scynexis, Inc.","briefTitle":"Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)","officialTitle":"Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-15","primaryCompletion":"2023-04-14","completion":"2023-05-24","firstPosted":"2017-12-06","resultsPosted":"2024-07-03","lastUpdate":"2024-07-03"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Candidiasis, Invasive","Candidemia"],"interventions":[{"type":"DRUG","name":"SCY-078","otherNames":[]}],"arms":[{"label":"SCY-078","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, open-label, non-comparator, single-arm study to evaluate the efficacy, safety, tolerability and PK (pharmacokinetics) of oral SCY-078 as an emergency use treatment for patients with a documented Candida auris infection.","primaryOutcome":{"measure":"Percentage of Participants With Global Success at End of Treatment as Determined by the Data Monitoring Committee","timeFrame":"At (EoT) Visit (up to 90 days after Day 1)","effectByArm":[{"arm":"Ibrexafungerp 750mg","deltaMin":21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":12,"countries":["United States","India","Pakistan","South Africa"]},"refs":{"pmids":["28483955","28223375"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":30},"commonTop":["Diarrhoea","Nausea","Vomiting","Candida infection","Constipation"]}}